Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
US8859572B2 · kind B2 · utility
9Cited by
1References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 13, 2009 |
| Grant date | Oct 14, 2014 |
| Priority date | — |
| Expiry date | Nov 15, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to novel sulfone 2I3-dihydroimidazo[1 l2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis mediated disorders, as a sole agent or in combination with other active ingredients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.